#USA #Fort Lee #PLGD-1 #Kedrion #Plasminogen Deficiency

Raising Awareness for Plasminogen Deficiency

Kedrion Biopharma is taking significant steps to raise awareness about Plasminogen Deficiency (PLGD-1) with a series of events held on May 5. These activities aim to educate both the general public and healthcare professionals about this rare genetic condition that affects approximately 1.6 individuals per million globally. Unveiling the seriousness of PLGD-1, the company has organized virtual interactions, digital campaigns, and in-person discussions that collectively focus on spreading vital information regarding the disorder.

PLGD-1 is a rare but serious condition characterized by abnormal fibrin-rich lesions that can emerge on mucosal surfaces. If left untreated or undiagnosed, people affected by PLGD-1 may experience severe complications, including loss of vision and hearing, airway obstructions, and infertility. Acknowledging PLGD Day, which is celebrated annually on May 4, Kedrion shifted its main events to May 5 to maximize outreach and engagement.

The specific goal of these initiatives is to inform the public about the symptoms associated with PLGD-1, the essential nature of early diagnosis, and ways to contribute to broader knowledge about this disorder. Even simple actions such as sharing relevant information on social media platforms or initiating a conversation with a healthcare provider can be instrumental in elevating awareness about this rare condition.

Important Facts about Plasminogen Deficiency

• - Widespread Impact: PLGD-1 is linked to serious health issues affecting various organs in the body.
• - Clinical Presentation: Patients often exhibit ligneous lesions on mucosal membranes, run the risk of being misdiagnosed, and might be viewed similarly to more common conditions like conjunctivitis.
• - Critical Need for Awareness: Increasing awareness is important to ensure timely diagnosis and access to appropriate treatment options.

During this year’s events, diverse stakeholders came together, including healthcare professionals and patients who shared their personal experiences and insights regarding PLGD-1. Bob Rossilli, CCO, Global Business and US General Manager, emphasized Kedrion's commitment to supporting PLGD-1 patients and the importance of collaboration with medical communities and advocacy groups. This collective effort aims to amplify awareness, foster research, and empower individuals suffering from this condition to lead more fulfilling and healthier lives.

Anita Brikman, President and CEO of the Plasma Protein Therapeutic Association, commended Kedrion's diligence in not only raising awareness for PLGD-1 but also in offering a viable treatment through its FDA-approved therapy. The organization highlighted the significance of PLGD Awareness Day as it offers a unique chance to focus on the needs and challenges faced by this specific patient community.

Presently, the documented cases of PLGD-1 are fewer than 500 in the US and only about 12,000 globally. Despite its rarity, early diagnosis is feasible through a straightforward laboratory test, underscoring the necessity for heightened awareness and improved diagnostic rates.

Rebecca Bialas, MD, who co-founded the Plasminogen Deficiency Foundation and is also a mother to two children affected by this condition, expressed a mixture of hope and sorrow. Reflecting on the growth of the PLGD-1 awareness community since her family's diagnosis, she praised Kedrion's relentless efforts in education and resource provision, emphasizing their life-altering impact.

Kedrion encourages individuals and families to learn more about PLGD-1 and contribute to raising awareness. More information can be found on their dedicated website, parting the clouds on Plasminogen Deficiency Type 1. Their overarching aim is to support those impacted by this rare condition, ensuring that every voice counts in the movement toward better understanding and treatment.

In conclusion, through events like Plasminogen Deficiency Awareness Day, Kedrion Biopharma is not only creating awareness but also fostering a community of support for individuals affected by PLGD-1. By participating in these discussions and initiatives, everyone has a chance to make a significant difference in the lives of those managing this often-overlooked condition.